Kalaris Therapeutics (KLRS) Operating Expenses (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Operating Expenses of -$977000.0 for Q1 2026, up 38.98% year-over-year from -$703000.9 in Q1 2025, and down 21.67% quarter-over-quarter from -$803000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Operating Expenses (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at -$977000.0 for Q1 2026.
- In Q1 2026, Operating Expenses rose 38.98% year-over-year to -$977000.0; the TTM figure through Mar 2026 stood at $9.6 million (down 8.9% YoY), while the FY2025 annual figure was -$4.2 million, down 128.21% from the prior year.
- Operating Expenses for Q1 2026 stood at -$977000.0, down from -$803000.0 in the prior quarter.
- The five-year high for Operating Expenses was $62.4 million in Q4 2023, with the low at -$29.9 million in Q4 2024.
- The 5-year median for Operating Expenses is $37.8 million (2024), against an average of $23.1 million.
- Peak annual rise in Operating Expenses reached 192.72% in 2025, while the deepest fall reached 309.01% in 2025.
- Kalaris Therapeutics' Operating Expenses stood at $40.4 million in 2022, then jumped by 54.34% to $62.4 million in 2023, then slumped by 147.86% to -$29.9 million in 2024, then soared by 97.31% to -$803000.0 in 2025, then dropped by 21.67% to -$977000.0 in 2026.
- Business Quant data shows KLRS's Operating Expenses at -$977000.0 in Q1 2026, -$803000.0 in Q4 2025, and -$847000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Kalaris Therapeutics | 95.90 Mn | 95.90 Mn | - | 12.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.39 Mn |
| Mar 31, 2026 | -977,000.00 |
| Dec 31, 2025 | -803,000.00 |
| Sep 30, 2025 | -847,000.00 |
| Jun 30, 2025 | 12.26 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -29.87 Mn |
| Sep 30, 2024 | 37.85 Mn |
| Jun 30, 2024 | 4.19 Mn |
| Mar 31, 2024 | 766,000.00 |
| Dec 31, 2023 | 62.41 Mn |
| Sep 30, 2023 | 46.96 Mn |
| Jun 30, 2023 | 47.30 Mn |
| Mar 31, 2023 | 43.23 Mn |
| Dec 31, 2022 | 40.43 Mn |
| Sep 30, 2022 | 42.95 Mn |
| Jun 30, 2022 | 44.62 Mn |
| Mar 31, 2022 | 43.19 Mn |
| Dec 31, 2021 | 55.80 Mn |
| Sep 30, 2021 | 45.50 Mn |